Anthem Biosciences — 360° view

Anthem Biosciences, a company in the Biotechnology industry, reported revenue of ₹594 crore and net profit of ₹211 crore for the September 2026 quarter.

Anthem Biosciences (NSE: ANTHEM) closed at ₹951.05 on 20 Nov 2026, up 46.9% over the past year. Its market capitalisation is ₹53,589 crore and it trades at 84.9 times earnings.

Share price
₹951.05 (20 Nov 2026)
Market cap
₹53,589 Cr (20 Nov 2026)
P/E
84.88 (20 Nov 2026)
Revenue
₹594 Cr (September 2026 quarter)
Net profit
₹211 Cr (September 2026 quarter)
ROCE
30.4% (FY26)
ROE
22.3% (FY26)
Book value
₹58.2 (FY26)
Dividend yield
0.21% (last 12 months to 20 Nov 2026)
52-week high / low
₹989.10 / ₹579.15 (20 Nov 2026)
1-year return
46.9% (to 20 Nov 2026)
Sector
Healthcare
Industry
Biotechnology
Symbol
NSE: ANTHEM

Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.